简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

12 Health Care Stocks Moving In Friday's After-Market Session

2025-08-23 05:07

Gainers

  • OSR Holdings (NASDAQ:OSRH) shares rose 34.6% to $0.7 during Friday's after-market session. The company's market cap stands at $9.1 million.
  • Nexalin Technology (NASDAQ:NXL) shares increased by 18.62% to $1.21. The market value of their outstanding shares is at $12.7 million.
  • Zymeworks (NASDAQ:ZYME) stock rose 6.62% to $16.1. The market value of their outstanding shares is at $1.0 billion.
  • NRX Pharmaceuticals (NASDAQ:NRXP) shares rose 6.06% to $2.8. The company's market cap stands at $49.8 million. The company's, Q2 earnings came out 4 days ago.
  • Cosciens Biopharma (NASDAQ:CSCI) shares rose 5.53% to $3.43. The company's market cap stands at $8.4 million.
  • Vivos Therapeutics (NASDAQ:VVOS) stock increased by 5.47% to $4.43. The company's market cap stands at $27.0 million. As per the press release, Q2 earnings came out 3 days ago.

Losers

  • ModivCare (NASDAQ:MODV) shares decreased by 9.3% to $0.97 during Friday's after-market session. The market value of their outstanding shares is at $8.0 million.
  • Wellgistics Health (NASDAQ:WGRX) shares declined by 5.77% to $0.89. The market value of their outstanding shares is at $57.2 million.
  • Jin Medical International (NASDAQ:ZJYL) stock declined by 5.43% to $0.69. The company's market cap stands at $89.4 million. As per the news, the H1 earnings report came out 2 days ago.
  • SciSparc (NASDAQ:SPRC) stock decreased by 5.32% to $4.45. The company's market cap stands at $2.2 million.
  • Evoke Pharma (NASDAQ:EVOK) stock fell 5.07% to $5.25. The company's market cap stands at $9.8 million.
  • Applied Therapeutics (NASDAQ:APLT) stock declined by 5.01% to $0.49. The market value of their outstanding shares is at $74.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。